Business

Medicamen Biotech : Disclosure under SEBI Takeover Regulations


Disclosures under Regulation 31(1)/31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

DETAILS OF

PROMOTER HOLDING

PROMOTER HOLDING

DETAILS OF EVENTS

POST EVENT HOLDING

NAME(S) OF

EVENTS

IN THE TARGET

ALREADY

PERTAINING TO

OF ENCUMBERED

TYPE OF

PERTAINING TO

COMPANY

ENCUMBERED

ENCUMBRANCE

SHARES

PROMOTER

COMPANY

REGULATION

AND/OR

EVENT –

ENCUMBRANCE –

% OF

% OF

% OF

% OF

SYMBOL

CREATION/REL

DATE OF

NAME

TYPE

PERSONS IN

EASE/INVOCAT

CREATION/

TOTAL

TOTAL

TOTAL

TOTAL

PROMOTER

ION

RELEASE/

NUMBER

EQUITY

NUMBER

EQUITY

NUMBER

EQUITY

NUMBER

EQUITY

GROUP

INVOCATION OF

SHARE

SHARE

SHARE

SHARE

ENCUMBRANCE

CAPITAL

CAPITAL

CAPITAL

CAPITAL

MEDICAM

Medicamen

MANJU

Biotech

31(1)

Creation

07-Jun-2022

70000

0.57

50000

0.41

20000

0.16

70000

0.57

EQ

BANSAL

Limited

Disclaimer: SEBI Circular dated Mar 7, 2022 with regards to Automation of disclosure requirements under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST Regulations”)-System Driven Disclosures – Ease of doing business, as per circular point 8(iii) require the Stock Exchanges to disseminate on its website the disclosures required under SAST Regulations and received from the depositories, in a pdf format. The data/information displayed in this pdf file is based on the reports received from depositories and hence, the Exchange will not be responsible for any inaccurate/incorrect data/information. In case any discrepancy is noticed, the same can be informed to Listed companies, Stock Exchanges and Depositories

Disclaimer

Medicamen Biotech Ltd. published this content on 18 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 June 2022 17:23:03 UTC.



Source link

Leave a Reply

Your email address will not be published.